Advertisement

Therapy Regimens Used in Adjuvant and Neoadjuvant Treatment of the Discussed Tumor Types

  • K. Possinger
  • A. Schauer
  • F. Griesinger
  • A. C. Roever

Keywords

Breast Cancer Cervical Cancer Esophageal Cancer Clin Oncol Radiation Therapy Oncology Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Further Reading

  1. Abulafia O, Sherer DM (1995) Adjuvant chemotherapy in stage IB neuroendocrine small cell carcinoma of the cervix. Acta Obstet Gynecol Scand 74(9):740–744PubMedGoogle Scholar
  2. Agarwala SS, Kirkwood JM (2002) Update on adjuvant interferon therapy for high-risk melanoma. Oncology (Huntingt) 16(9):1177–1187; discussion 1190–1192; 1197PubMedGoogle Scholar
  3. Ajani JA, Faust J, Yao J, Komaki R, Stevens C, Swisher S, Putnam JB, Vaporciyan A, Smythe R, Walsh G, Rice D, Roth J (2003) Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncol (Huntingt) 17(9 Suppl 8):20–22Google Scholar
  4. Akakura K, Tsujii H, Morita S, Tsuji H, Yagishita T, Isaka S, Ito H, Akaza H, Hata M, Fujime M, Harada M, Shimazaki J (2004) Working Group for Genitourinary Tumors, National Institute of Radiological Science: phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate 58(3):252–258CrossRefPubMedGoogle Scholar
  5. Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y, Tsurumaru M, Sasai K (2003) c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 57(5):1323–1327CrossRefPubMedGoogle Scholar
  6. Akaza H (2004) Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer. BJU Int 93(1):42–46CrossRefPubMedGoogle Scholar
  7. Albanell J, Codony J, Rovira A, Mellado B, Gascon P (2003) Mechanism of action of anti-HER 2 monoclonal antibodies: scientific update on trastuzumab and 2 C4. Adv Exp Med Biol 532:253–268PubMedGoogle Scholar
  8. Alexanian A, Torri V (2000) Survey on the treatment of non-small-cell lung cancer in Italy. Ann Oncol 11(7):807–813CrossRefPubMedGoogle Scholar
  9. Amdur RJ, Mendenhall WM, Stringer SP, Villaret DB, Cassisi NJ (2001) Organ preservation with radiotherapy for T1-T2 carcinoma of the pyriform sinus. Head Neck 23(5):353–362CrossRefPubMedGoogle Scholar
  10. American College of Obstetricians and Gynecologists (2002) ACOG practice bulletin, Number 35, May 2002: Diagnosis and treatment of cervical carcinomas. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 78(1):79–91Google Scholar
  11. Antonadou D, Petridis A, Synodiniou M, Throuvalas N, Bolanos N, Veslemes M, Sagriotis A (2003) Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. Semin Oncol 30(6 Suppl 18):2–9Google Scholar
  12. ATAC Trialists’ Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139 (Epub: www.thelancet.com)Google Scholar
  13. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22(5):909–918CrossRefPubMedGoogle Scholar
  14. Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Di Bartolomeo M, Regalia E, Cassata A, Procopio G, Mariani L (1998) 5-Fluorouracil, dacarbazine and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 83(2):372–378PubMedGoogle Scholar
  15. Baranov SB, Guseinov KD (2003) Assessment of effectiveness of preoperative chemoradiotherapy in patients with T1B-2ABN0-1M0 cervical cancer. Vopr Onkol 49(5):612–614PubMedGoogle Scholar
  16. Barker JL Jr, Glisson BS, Garden AS, El-Naggar AK, Morrison WH, Ang KK, Chao KS, Clayman G, Rosenthal DI (2003) Management of nonsinonasal neuroendocrine carcinomas of the head and neck. Cancer 98(11):2322–2328CrossRefPubMedGoogle Scholar
  17. Bates D (2003) ZD-6474. AstraZeneca. Curr Opin Investig Drugs 4(12):1468–1472PubMedGoogle Scholar
  18. Berthold F, Hero B (2000) Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 59(6):1261–1277PubMedGoogle Scholar
  19. Boivin D, Gendron S, Beaulieu E, Gingras D, Beliveau R (2002) The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Mol Cancer Ther 1(10):795–802PubMedGoogle Scholar
  20. Bonadonna G, Valagussa P (1995) Combined modality approach for high risk breast cancer. The Milan Cancer Institute experience. Surg Oncol Clin North Am 4(4):701–714Google Scholar
  21. Bonadonna, G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate and fluoruracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332(14):901–906CrossRefPubMedGoogle Scholar
  22. Boruta DM 2nd, Schorge JO, Duska LA, Crum CP, Castrillon DH, Sheets EE (2001) Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix. Gynecol Oncol 81(1):82–87CrossRefPubMedGoogle Scholar
  23. Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, Johnson G, Wolf GT, Fisher SG, Carey TE (2003) P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25(8):654–661CrossRefPubMedGoogle Scholar
  24. Brentjens R, Saltz L (2001) Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am 81(3):527–542CrossRefPubMedGoogle Scholar
  25. Buda A, Dell'Anna T, Signorelli M, Mangioni C (2003) Role of ifosfamide in cervical cancer: an overview. Oncology 65(Suppl 2):63–66CrossRefPubMedGoogle Scholar
  26. Bukowski RM (2003) AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma. Expert Opin Investig Drugs 12(8):1403–1411CrossRefPubMedGoogle Scholar
  27. Buzdar AU (2003 a) Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC Trial. Clin Breast Cancer 4(Suppl 1):S42–S48PubMedGoogle Scholar
  28. Buzdar AU (2003 b) Role of anastrozole in adjuvant therapy for postmenopausal patients. Semin Oncol 30(5 Suppl 16):21–29CrossRefGoogle Scholar
  29. Buzdar AU, Plourde PV, Hortobagyi GN (1996 a) Aromatase inhibitors in metastatic breast cancer. Semin Oncol 23(4 Suppl 9):28–32Google Scholar
  30. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV (1996b) Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials (Arimidex Study Group). J Clin Oncol 14(7):2000–2011PubMedGoogle Scholar
  31. Caine GJ, Stonelake PS, Rea D, Lip GY (2003 a) Coagulopathic complications in breast cancer. Cancer 98(8):1578–1586CrossRefPubMedGoogle Scholar
  32. Caine GJ, Lip GY (2003 b) Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients? Arch Intern Med 163(10):1243–1244CrossRefGoogle Scholar
  33. Calvo E, Cortes J, Rodriguez J, Fernandez-Hidalgo O, Rebollo J, Martin-Algarra S, Garcia-Foncillas J, Martinez-Monge R, de Irala J, Brugarolas A (2002) Irinotecan, oxaliplatin and 5-fluorouracil/leukovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. Clin Colorectal Cancer 2(2):104–110PubMedGoogle Scholar
  34. Canellos GP, Hellman S, Veronesi U (1982) The management of early breast cancer (occasional notes). N Engl J Med 306:1430–1432PubMedGoogle Scholar
  35. Cassinello J, Escudero P, Salud A, Marcos F, Pujol E, Perez-Carrion R, Colmenarejo A, Gonzalez del Val R, Valero J, Oruezabal MJ, Guillem V, Carcia I, Arcediano A, Marfa X (2003) Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. Clin Colorectal Cancer 3(2):108–112PubMedGoogle Scholar
  36. Castaglione F, Porcile G, Gridelli C (2000) The potential role of amifostine in the treatment of non small cell lung cancer. Lung Cancer 29(1):57–66CrossRefPubMedGoogle Scholar
  37. Castro DJ, Sridhar KS, Garewal HS, Mills GM, Wenig BL, Dunphy FR 2nd, Costatino PD, Leavitt RD, Stewart ME, Orenberg EK (2003) Intratumoral cisplatin/epinephrine gel in advanced head and neck cancer: a multicenter, randomized, double-blind, phase III study in North America. Head Neck 25(9):717–731CrossRefPubMedGoogle Scholar
  38. Cervantes et al (2000) Capecitabine monotherapy in taxane-resistent disease (n = 32). ASCO, Abstract 469Google Scholar
  39. Choi NC (2003) Radioprotective effect of amifostine in radiation pneumonitis. Semin Oncol 30(6 Suppl 18):10–17CrossRefGoogle Scholar
  40. Cobleigh MA (2000) MBCC. From: Slamon et al (1999) Results from the pivotal anti-HER2-fherapy/chemotherapy combination study. ECCO, Abstract 1261Google Scholar
  41. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbach L, Wolter JM, Paton V, Shak S, Liebermann G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648PubMedGoogle Scholar
  42. Colleoni M, Litman HJ, Castiglione-Gertsch M, Sauerbrei W, Gelber RD, Bonetti M, Coates AS, Schumacher M, Bastert G, Rudenstam C-M, Schmoor C, Lindtner J, Collins J, Thurlimann B, Holmberg SB, Crivellari D, Beyerle C, Neumann RLA, Goldhirsch A for the International Breast Cancer Study Group and the German Breast Cancer Study Group (2002) Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer 86(11):1705–1714CrossRefPubMedGoogle Scholar
  43. Crosby TD, Brewster AE, Borley A, Perschky L, Kehagioglou P, Court J, Maughan TS (2004) Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer 90(1):70–75CrossRefPubMedGoogle Scholar
  44. Culine S, Rebillard X, Iborra F, Mottet N, Faix A, Ayuso D, Pinguet F (2003) Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study. Anticancer Res 23(2 C):1903–1906PubMedGoogle Scholar
  45. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T (IBIS investigators) (2004) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360(9336):817–824Google Scholar
  46. Cykert S (2003) Tamoxifen for breast-cancer prevention. Lancet 361(9352):177–178CrossRefGoogle Scholar
  47. Darnton SJ, Archer VR, Stocken DD, Mulholland PJ, Casson AG, Ferry DR (2003) Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival. J Clin Oncol 21(21):4009–4015CrossRefPubMedGoogle Scholar
  48. De Jong M, Bakker WH, Breeman WA, Bernard BF, Hofland LJ, Visser TJ, Srinivasan A, Schmidt M, Behe M, Macke HR, Krenning EP (1998) Pre-clinical comparison of (DTPA0- Tyr3)octreotide and (DTPA0-D-Phe1-Tyr3) octreotide as carriers for somatostatin receptor targeted scintigraphy and radionuclide therapy. Int J Cancer 75:406–411CrossRefPubMedGoogle Scholar
  49. de Wit R (European Organization for Research and Treatment) (2003) Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer 97(8 Suppl):2120–2126PubMedGoogle Scholar
  50. Di Cosimo S, Ferretti G, Fazio N, Silvestris N, Carlini P, Alimonti A, Gelibter A, Felici A, Papaldo P, Gognetti F (2003) Docetaxel in advanced gastric cancer — review of the main clinical trials. Acta Oncol 42(7):693–700CrossRefPubMedGoogle Scholar
  51. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16(2):453–461PubMedGoogle Scholar
  52. Donskov F, Marcussen N, Hokland M, Fisker R, Madsen HH, von der Maase H (2004) In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67(MIB-1) in patients with metastatic renal cell carcinoma. Br J Cancer 90(3):626–631CrossRefPubMedGoogle Scholar
  53. Dutcher JP, Fine JP, Krigel RL, Murphy BA, Schaefer PL, Ernstoff MS, Loehrer PJ (2003) Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Med Oncol 20(3):271–281PubMedGoogle Scholar
  54. Eastham JA (2004) Multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy in high-risk localised prostate cancer. Expert Opin Investig Drugs 13(1):39–46CrossRefPubMedGoogle Scholar
  55. Eberhardt W, Wolf M (2001) Chemotherapy in stage IV lung cancer (take home messages). Lung Cancer 33(Suppl 1):S121–123CrossRefPubMedGoogle Scholar
  56. Eberhardt W, Wilke H, Stamatis G, Stuschke M, Jarstrick A, Menker H, Krause B, Müller MR, Stahl M, Flasshove M, Budach V, Greschuchna D, Konietzko N, Sack H, Seeber S (1998) Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trail. J Clin Oncol 16:622–634PubMedGoogle Scholar
  57. Eberhardt W, Stamatis G, Stuschke M, Wilke H, Müller MR, Kolks S, Flasshove M, Schutte J, Stahl M, Schlenger L, Budach V, Greschuchna D, Stuben G, Teschler H, Sack H, Seeber S (2000) Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial. Br J Cancer 81(7):1206–1212CrossRefGoogle Scholar
  58. Einhorn N, Trope C, Ridderheim M, Boman K, Sorbe B, Cavllin-Stahl E (2003) A systematic overview of radiation therapy effects in cervical cancer (cervix uteri). Acta Oncol 42(5/6):546–556CrossRefPubMedGoogle Scholar
  59. Elias A, Ibrahim S, Skarin AT, Wheeler C, McCauley M, Ayash L, Richardson P, Schipper L, Antman KH, Frei X 3rd (1999) Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol 17(4):1175PubMedGoogle Scholar
  60. Ellis MJ (2004) Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy. Ann Surg Oncol 11(1 Suppl):S9–17Google Scholar
  61. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans D, Dugan M, Brady C, Quebe-Fehling E, Borgs M (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer. J Clin Oncol 19(18): 3808–3816PubMedGoogle Scholar
  62. Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB, Miller WR (2003 a) Letrozole inhibitis tumor proliferation more effectively than tamoxifen independent of HER 1/2 expression status. Cancer Res 63(19): 6523–6531PubMedGoogle Scholar
  63. Ellis MJ, Rosen E, Dressman H, Marks J (2003 b) Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. J Steroid Biochem Mol Biol 86(3–5):301–307CrossRefPubMedGoogle Scholar
  64. Evans TL (2000) Highlights from the Tenth World Conference on Lung Cancer. Oncologist 9(2):232–238CrossRefGoogle Scholar
  65. Faiss S, Scherubl H, Riecken EO, Wiedenmann B (1996) Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Recent Results Cancer Res 142:193–207PubMedGoogle Scholar
  66. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Constantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph-nodes and estrogen receptor positive tumors. J Natl Cancer Inst 88(21):1529–1542PubMedGoogle Scholar
  67. Flux GD, Guy MJ, Papavasileiou P, South C, Chittenden SJ, Flower MA, Meller ST (2003) Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mlBG. Cancer Biother Radiopharm 18(1):81–87CrossRefPubMedGoogle Scholar
  68. Frank M, Kose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R (1999) Combination therapy with octreotide and alpha-interferon: effect on tumour growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94(5):1381–1387PubMedGoogle Scholar
  69. Friedberg V (1988) Operative therapy for stage IIb cervical cancer. In: Burghardt E, Monaghan JM (eds) Operative treatment of cervical cancer. (Baillière's Clinical obstetrics and gynaecology, vol 2). Bailliere Tindall, London, pp 973–980Google Scholar
  70. Fukuoka M (2000) Current perspectives of new agents in lung cancer. Nippon Rinshi 58(5):1103–1110Google Scholar
  71. Garaventa A, Boni L, Piccolo MS, Tonini GP, Gambini C, Mancini A, Tonegatti L, Carli M, di Montezemolo LC, Di Cataldo A, Casale F, Mazzocco K, Cecchetto G, Rizzo A, Bernardi B, for the Italian Cooperative Group for Neuroblastoma (2002) Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol 13(6):956–964CrossRefPubMedGoogle Scholar
  72. George S, Yunus F, Case D, Yang B-B, Hackett J, Shogan JE, Meza LA, Neumann TA, Liang BC (2003) Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 44(10):1691–1696CrossRefPubMedGoogle Scholar
  73. German Cancer Society (2000) Guidelines for cancer treatment. Zuckschwerdt, Munich Berne Vienna New YorkGoogle Scholar
  74. Gingras D, Batist G, Beliveau R (2001) AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. Expert Rev Anticancer Ther 1(3):341–347PubMedGoogle Scholar
  75. Ginsberg RJ (2000) Multimodality treatment of resectable non small-cell lung cancer. Clin Lung Cancer 1(3):194–200; discussion 201PubMedGoogle Scholar
  76. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findle BP, Pitot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leukovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1):23–30CrossRefPubMedGoogle Scholar
  77. Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS (2001a) Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 30:44–51PubMedGoogle Scholar
  78. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ (2001b) Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19(18):3817–3827PubMedGoogle Scholar
  79. Goldhirsch A, Colleoni M, Gelber RD (2002) Endocrine therapy of breast cancer. Ann Oncol 13(Suppl 4):61–68CrossRefGoogle Scholar
  80. Greco FA (2003) Topotecan as first-line therapy for small cell lung cancer. Lung Cancer 41(Suppl 4):S9–16CrossRefGoogle Scholar
  81. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ, on behalf of the International Pegfilgrastim 749 Study Group (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29–35CrossRefPubMedGoogle Scholar
  82. Gridelli C, Cigolaris S, Maiorino A, Ianniello GP, Brancaccio L, Rossi A, DeCataldis G, Pedicini T, Maiorino L, Barletta E, Di Lanno M, Bilancia D, Crisipino C, Barzelloni ML, Masullo P, D'Anille R, Manzione L (2000) Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: A multicenter phase II study. Lung Cancer 28:237–244CrossRefPubMedGoogle Scholar
  83. Grigg A, Solal-Celigny Ph, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J, Hiddemann W on behalf of an International Study Group (2003) Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 44(9): 1503–1508PubMedGoogle Scholar
  84. Hacker NF, Wain GV, Nicklin JL (1995) Resection of bulky positive lymph-nodes in patients with cervical carcinoma. Int J Gynecol Cancer 5:250–256CrossRefPubMedGoogle Scholar
  85. Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU (2003) RTOG 97-06: initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57(3):665–672CrossRefPubMedGoogle Scholar
  86. Hakansson A, Hakansson L, Gustafsson B, Krysander L, Rettrup B, Ruiter D, Bernsen MR (2003) On the effect of biochemotherapy in metastatic malignant melanoma: an immunopathological evaluation. Melanoma Res 13(4): 401–407CrossRefPubMedGoogle Scholar
  87. Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M (2004) Adjuvant interferon in high-risk melanoma: the AIM HIGH Study — United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alpha-2a in high-risk resected malignant melanoma. J Clin Oncol 22(1):53–61; Epub Dec 09CrossRefPubMedGoogle Scholar
  88. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandier HM, Shipley WU on behalf of the Radiation Therapy Oncology Group (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21(21):3972–3978CrossRefPubMedGoogle Scholar
  89. Hansen HH, Roth M (1999) Lung cancer. Cancer Chemother Biol Response Modif 18:336–356PubMedGoogle Scholar
  90. Hatton MQ, Reed NS (1997) Chemotherapy for neuroendocrine tumors: Beatson Oncology Centre experience. Clin Oncol (R Coll Radiol) 9(6):385–389Google Scholar
  91. Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, Schulte KW, Ring J, Schadendorf D, Lischner S, Burg G, Dummer R (2003) Prospective randomized trial of interferon alpha-2b and interleukin-2 as adjuvant treatment for resected intermediate-and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 21(15):2883–2888CrossRefPubMedGoogle Scholar
  92. Heppeler A, Froidevaux S, Maecke HR, Jermann E, Behe M, Powell P, Henning M (1999) Radiometal labelled macrocyclic chelator derivatised somatostatin analogue with supperb tumour targeting properties and potential for receptor mediated internal radiotherapy. Chem Eur J 5:1974–1981CrossRefGoogle Scholar
  93. Hernberg M, Virkunen P, Bono P, Ahtinen H, Maenpaa H, Joensuu H (2003) Interferon alpha-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 21(20):3770–3776CrossRefPubMedGoogle Scholar
  94. Hersey P, Menzies SW, Halliday GM, Nguyen T, Farrelly ML, DeSilva C, Lett M (2004) Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 53(2):125–134; Epub Nov 05CrossRefPubMedGoogle Scholar
  95. Holmes FA, Jones SE, O'shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang B-B, Liang BC (2002 a) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13:903–909CrossRefPubMedGoogle Scholar
  96. Holmes FA, O'shaughnessy S, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BD (2002 b) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20(3):727–731CrossRefPubMedGoogle Scholar
  97. Holtz DO, Dunton C (2002) Traditional management of invasive cervical cancer. Obstet Gynecol Clin North Am 29(4):645–657CrossRefPubMedGoogle Scholar
  98. Horiguchi A, Uchida A (2004) Advanced renal cell carcinoma showing a different response to two types of interferon-alpha. Nippon Hinyokika Gakkai Zasshi 95(1):50–53PubMedGoogle Scholar
  99. Hurwitz et al (2003) Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 22: abstr 3646Google Scholar
  100. Jain RK (2002) Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor. Semin Oncol 29(Suppl 16):3–9CrossRefGoogle Scholar
  101. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, Yang B, Gardner SH, Miller-Messana MA, Shoemaker D, Garst J, Schwab G (2000) Randomized dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18(13):2522–2528PubMedGoogle Scholar
  102. Joss R (2000) Recent developments in the treatment of lung cancer: from the point of view of the medical oncologist. Schweiz Med Wochenschr 130:684–690PubMedGoogle Scholar
  103. Kaasinen E, Wijkstrom H, Malmstrom PU, Hellsten S, Duchek M, Mestad O, Rintala E on behalf of Nordic Urothelial Cancer Group (2003) Alternating mitomycin C and BCG installations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordig study. Eur Urol 43(6):637–645PubMedGoogle Scholar
  104. Kabbinavar, Hurwitz HI, Ferenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin(LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65CrossRefPubMedGoogle Scholar
  105. Kalmar K, Cseke L, Kaposztas Z, Horvath G, Varga E (2003) Neoadjuvant chemotherapy for locally advanced gastric cancer. Magy Seb 56(5):177–184PubMedGoogle Scholar
  106. Kaltsas GA, Mukherjee JJ, Isidori A, Kola B, Plowman PN, Monson JP, Grossman AB, Besser GM (2002) Treatment of advanced neuroendocrine tumors using combination chemotherapy with lomustine and 5-fluorouracil. Clin Endocrinol (Oxf) 57(2):169–183CrossRefGoogle Scholar
  107. Kefford RF (2003) Adjuvant therapy of cutaneous melanoma: the interferon debate. Ann Oncol 14(3):358–365CrossRefPubMedGoogle Scholar
  108. Kerbel RS (2004) Antiangiogenic drugs and current strategies for the treatment of lung cancer. Semin Oncol 31(1 Suppl 1):54–60Google Scholar
  109. Keresztes RS, Port JL, Pasmantier MW, Korst RJ, Altorki NK (2003) Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial. J Thorac Cardiovasc Surg 126(5):1603–1608CrossRefPubMedGoogle Scholar
  110. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CHL III, Walker JL, Gersell D (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage Ib cervical carcinoma. N Engl J Med 340:1154–1161CrossRefPubMedGoogle Scholar
  111. Kleeberg UR, Suciu S, Brocker EB, Ruiter DJ, Chartier C, Lienard D, Marsden J, Schadendorf D, Eggermont AM, EORTC Melanoma Group in cooperation with the German Cancer Society (DKG) (2004) Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 40(3):390–402CrossRefPubMedGoogle Scholar
  112. Krenning EP, Bakker WH, Breemann WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC, Lamberts SW (1989) Localisation of endocrine related tumours with radioiodinated analogue somatostatin. Lancet 1:242–244CrossRefPubMedGoogle Scholar
  113. Kretschmer L, Helmbold P, Emmert S, Marsch WC (2002) Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma. Hautarzt 53(8):536–541CrossRefPubMedGoogle Scholar
  114. Kubista E, Glaspy J, Holmes A, Green MD, Hackett J, Neumann T on behalf of the pegfilgrastim study group (2003) Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer 3(6):391–398PubMedGoogle Scholar
  115. Kumamoto Y, Masuda M, Kuratomi Y, Toh S, Shinokuma A, Chujo K, Yamamoto T, Komiyama S (2002) “FAR” chemotherapy improves laryngeal preservation rates in patients with T2N0 glottic carcinoma. Head Neck 24(7): 637–642CrossRefPubMedGoogle Scholar
  116. Kushner BH, Yeh SD, Kramer K, Larson SM, Cheung NK (2001) Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 21(6):1082–1086CrossRefGoogle Scholar
  117. Laurie SA, Kris MG (2000) Single-agent docetaxel (taxotere) in the treatment of advanced non-small-cell lung cancer: clinical concepts and commentary. Clin Lung Cancer 1(Suppl 1):S5–9PubMedGoogle Scholar
  118. Lawenda BD, Thiringer JK, Foss RD, Johnstone PA (2001) Merkel cell carcinoma arising in the head and neck: optimizing therapy. Am J Clin Oncol 24(1):35–42CrossRefPubMedGoogle Scholar
  119. Lens MB, Reiman T, Husain AF (2003) Use of tamoxifen in the treatment of malignant melanoma. Cancer 98(7): 1355–1361CrossRefPubMedGoogle Scholar
  120. Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16(8):2651–2658PubMedGoogle Scholar
  121. Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21:3965–3971CrossRefPubMedGoogle Scholar
  122. Lorente JA, Arango O, Bielsa O, Cortadellas R, Canis D, Lloreta-Trull J, Gelabert-Mas A (2003) Comparative study of the effect of complete prolonged neoadjuvant hormonal blockade versus standard hormonal blockade. Actas Urol Esp 27(9):678–683PubMedGoogle Scholar
  123. Lu C, Komaki R, Lee JS, Shin DM, Palmer JL, Coldman BJ, Pisters KM, Kurie JM, Fossell FV, Glisson BS (2003) A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clin Cancer Res 9(6):2085–2091PubMedGoogle Scholar
  124. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10):725–730CrossRefPubMedGoogle Scholar
  125. Marinelli (2000) Individual activity estimation. Cited in German Cancer Society (2000)Google Scholar
  126. Mariani SM (2003) Anti-angiogenesis: the challenges ahead. Med Gen Med 5(2):22Google Scholar
  127. Marsh JC, Catalano P, Huang J, Graham DL, Cornfeld MJ, O'Dwyer PJ, Benson AB 3rd (2002) Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. Clin Colorectal Cancer 2(1):43–50PubMedGoogle Scholar
  128. Martinez A, Galalae R, Gonzalez J, Mitchell C, Gustafson G, Kovacs G (2003) No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose. J Urol 170(6 Pt 1):2296–2301CrossRefPubMedGoogle Scholar
  129. Martini N, Kris MG, Flelinger BJ, Gralla RJ, Brains MS, Burt ME, Heelan R, McCormack PM, Pisters KM, Rigas JR, Rusch VW, Grinsberg RJ (1993) Preoperative chemotherapy for stage IlIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorc Surg 55(6):1365–1373Google Scholar
  130. McKinnon JG (1993) Palliative treatment of neuroendocrine tumors. Semin Surg Oncol 9(5):453–458PubMedGoogle Scholar
  131. Medalie NS, Ackerman AB (2003 a) Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma metastatic to a lymph node: an assertion based on comprehensive, critical analysis: part I. Am J Dermatopathol 25(5):399–417PubMedGoogle Scholar
  132. Medalie NS, Ackerman AB (2003 b) Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma metastatic to a lymph node: an assertion based on comprehensive, critical analysis: part II. Am J Dermatopathol 25(6):473–484PubMedGoogle Scholar
  133. Meliani E, Lapini A, Serni S, Corvino C, Carini M (2003) Gemcitabine plus cisplatin in adjuvant regimen for bladder cancer. Toxicity evaluation. Urol Int 71(1):37–40CrossRefPubMedGoogle Scholar
  134. Meluch AA, Greco FA, Burris HA 3rd, O'Rourke T, Ortega S, Steis RG, Morrissey LH, Johnson V, Hainsworth JD (2001) Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 19(12):3018–3024PubMedGoogle Scholar
  135. Miano M, Garaventa A, Pizzitola MR, Piccolo MS, Dallorso S, Villavecchia GP, Bertolazzi C, Cabria M, De Bernardi B (2001) Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant 27(6):571–574CrossRefPubMedGoogle Scholar
  136. Milas L, Mason KA, Liao Z, Ang KK (2003) Chemotherapy: emerging treatment improvement strategies. Head Neck 25(2):152–167CrossRefPubMedGoogle Scholar
  137. Miller VA (2000) Trials of venorelbine and docetaxel in the treatment of advanced non small-cell lung cancer. Clin Lung Cancer 1(Suppl 1):S24–26PubMedGoogle Scholar
  138. Moertel CG, Kvols LK, O'Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 68:227PubMedGoogle Scholar
  139. Mohr P, Weichenthal M, Hauschild A (2003) Adjuvant therapy in melanoma. Onkologie 26(3):227–233CrossRefPubMedGoogle Scholar
  140. Molife R, Hancock BW (2002) Adjuvant therapy of malignant melanoma. Crit Rev Oncol Hematol 44(1):81–102PubMedGoogle Scholar
  141. Monroe AT, Hinerman RW, Amdur RJ, Morris CG, Mendenhall WM (2003) Radiation therapy for esthesioneuroblastoma: rationale for elective neck irradiation. Head Neck 25(7):529–534CrossRefPubMedGoogle Scholar
  142. Nabeya Y, Ochiai T (2003) Chemotherapy for esophageal cancer. Gan To Kagaku Ryoho 30(12):1873–1880PubMedGoogle Scholar
  143. Nabholtz JM (2003) Docetaxel-anthracycline combinations in metastatic breast cancer. Breast Cancer Res Treat 79(Suppl 1):S3–9CrossRefPubMedGoogle Scholar
  144. Nabholtz JM, Cantin J, Chang J, Guevin R, Patel R, Tkaczuk K, Vodvarka P, Lindsay MA, Reese D, Riva A, Mackey J (2002) Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. Clin Breast Cancer 3(4):268–275PubMedGoogle Scholar
  145. Nashikimi T, Ishida R, Yamada H, Yokoi K, Kobayashi H, Obata K (2004) A case of multiple lung metastases and cervical lymph node metastasis of renal cell carcinoma failing to respond to interferon-alpha (IFN-alpha) but markedly responding to interleukin-2 (IL-2). Nippon Hinyokika Gakkai Zasshi 95(1):54–58PubMedGoogle Scholar
  146. National Institutes of Health (1997) Consensus Development Conference: consensus statement on cervical cancer. Gynecol Oncol 66:351–361Google Scholar
  147. NCI (1999) Clinical announcement: concurrent chemoradiation for cervical cancer. http://cancertrials.nci.nih.giv/NCI_CANCER_TRIALS/zones/TrialInfo/News/cervcan/clinann.htmlGoogle Scholar
  148. Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration (Cumulative Review) (2003) Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 39(17):2470–2486Google Scholar
  149. Niederle N, Krischke W, Bremer K, Schmidt CG, Seeber S (1982) Small-cell bronchogenic carcinoma — primary and relapse therapy with etoposide (VP16), methotrexate and CCNU. Cancer Treat Rev Suppl 101–105Google Scholar
  150. O'Byrne K, Steward WP (1999) The role of chemotherapy in the treatment of adult soft tissue sarcomas. Oncology 56(1):13–23CrossRefPubMedGoogle Scholar
  151. Oeberg K (1996) Neuroendocrine gastrointestinal tumours. Ann Oncol 7:453–463PubMedGoogle Scholar
  152. Oeberg K (1998) Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol 10:58–65PubMedGoogle Scholar
  153. Oeberg K (2003) Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 3(6):863–877CrossRefPubMedGoogle Scholar
  154. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, Heppeler A, Müller-Brand J, Maecke HR (1997) DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24:792–796PubMedGoogle Scholar
  155. Otte A, Müller-Brand J, Delias S, Nitzsche EU, Herrmann R, Maecke HR (1998) Yttrium-90 labelled somatostatin-analogue for cancer treatment. Lancet 351:417–418CrossRefPubMedGoogle Scholar
  156. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, Maecke HR, Müller-Brand J (1999) Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 26:1439–1447CrossRefPubMedGoogle Scholar
  157. Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, Villa E, Verusio C, Cetto GL, Santo A, De Pangher V, Artioli F, Cacciani GC, Parodi G, Soresi F, Ghi MG, Morabito A, Biason R, Giusto M, Mosconi P, Chiarion Sileni V; GSTVP (Gruppo di Studio Tumori Polmo-nari del Veneto) (2004) Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 43(1):83–91CrossRefPubMedGoogle Scholar
  158. Park YH, Ryoo BY, Choi SJ, Kim HT (2004) A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 90(7):1329–1333CrossRefPubMedGoogle Scholar
  159. Patel K, Anthoney DA, Crellin AM, Sebag-Montefiore D, Messruther J, Seymour MT (2004) Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose intensity in adjuvant chemotherapy after colorectal cancer resection. Ann Oncol 15(4):568–573CrossRefPubMedGoogle Scholar
  160. Patton SE, Hall MC, Ozen H (2002) Bladder cancer. Curr Opin Oncol 14(3):265–272CrossRefPubMedGoogle Scholar
  161. Pawlik TM, Sondak VK (2003) Malignant melanoma: current state of primary and adjuvant treatment. Crit Rev Oncol Hematol 45(3):245–264PubMedGoogle Scholar
  162. Pecorelli S (ed) (1998) FIGO Annual report on the results of treatment in gynaecological cancer (23rd). J Epidemiol Biostat 3:1–168Google Scholar
  163. Pectasides D, Glotsos J, Bountouroglou N, Kouloubines A, Mitakidis N, Karvounis N, Ziras NM, Athanassiou A (2002) Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol 13(2):243–250CrossRefPubMedGoogle Scholar
  164. Peyromaure M, Allouch M, Eschwege F, Verpillat P, Debre B, Zerbib M (2003) Salvage radiotherapy for biochemical recurrence after radical prostatectomy: a study of 62 patients. Urology 62(3):503–507CrossRefPubMedGoogle Scholar
  165. Pinheiro AD, Foote RL, McCaffrey TV, Kasperbauer JL, Bonner JA, Olsen KD, Cha SS, Sargent DJ (2003) Intraoperative radiotherapy for head and neck and skull base cancer. Head Neck 25(3):217–225; discussion 225–226CrossRefPubMedGoogle Scholar
  166. Pinkerton CR, Blanc Vincent MP, Bergeron C, Fervers B, Philip T (2000) Induction chemotherapy in metastatic neuroblastoma — does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC). Eur J Cancer 36(14):1808–1815CrossRefPubMedGoogle Scholar
  167. Pisansky TM (2003) Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer. Urology 62(Suppl 1):36–45CrossRefGoogle Scholar
  168. Pisters KM (2001) Adjuvant and neoadjuvant therapy for early stage non-small cell lung cancer. Semin Oncol 28(4 Suppl):23CrossRefGoogle Scholar
  169. Pisters KM, Ginsberg RJ, Giroux DJ, Putnam JB Jr, Kris MG, Johnson DH, Roberts JR, Mault J, Crowley JJ, Bunn PA Jr (2000) Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. J Thorac Cardiovasc Surg 119(3):429–439PubMedGoogle Scholar
  170. Piver MS, Rutledge F, Smith JP (1974) Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 44:265–272PubMedGoogle Scholar
  171. Polee MB, Hop WC, Kok TC, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Stoter G, van der Gaast A (2003) Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer 89(11): 2045–2050CrossRefPubMedGoogle Scholar
  172. Poon MA, O'Connell MJ, Wieland HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG, Maillieard JA (1991) Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9(11): 1967–1972PubMedGoogle Scholar
  173. Pottgen C, Eberhardt W, Bildat S, Stuben G, Stamatis G, Hillejan L, Sohrab S, Teschler H, Seeber S, Sack H, Stuschke M (2002) Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages Illa/IIIb): a pilot phase I/II trial. Ann Oncol 13(3):403–411CrossRefPubMedGoogle Scholar
  174. Potti A, Hille R, Koch M (2003) Immunohistochemical determination of HER-2/neu in malignant melanoma. Anticancer Res 23(5A):4067–4069PubMedGoogle Scholar
  175. Ravaud A, Trufflandier N, Ferriere JM, Debled M, Palussiere J, Cany L, Gaston R, Mathoulin-Pelissier S, Bui BN (2003) Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial. Br J Cancer 89(12):2213–2218CrossRefPubMedGoogle Scholar
  176. Reboul FL (2004) Radiotherapy and chemotherapy in locally advanced non-small-lung cancer: preclinical and early clinical data. Hematol Oncol Clin North Am 18(1):41–53CrossRefPubMedGoogle Scholar
  177. Recchia F, Sica G, DeFilippis S, Rosselli M, Saggio G, Guerriero G, Pompili P, Rea S (2000) Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study. Anticancer Res 20(3B):1985–1990PubMedGoogle Scholar
  178. Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, Ulm K, Hessler S, Gatzemeier U (2003) Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 95(15):1118–1127PubMedGoogle Scholar
  179. Renard A, Noel G, Mazeron JJ (2000) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non small-cell lung cancer. Cancer Radiother 4(4):317–318PubMedGoogle Scholar
  180. Roach M 3rd (2003) Hormonal therapy and radiotherapy for localized prostate cancer: who, where and how long? J Urol 170(6 Pt 2):S35–40; discussion S40–41CrossRefGoogle Scholar
  181. Rosell R (2002) Multicenter Trial of the Spanish Lung Cancer Study Group and the SAKK (Swiss Cancer Society) (arm A: preoperative, arm C: adjuvant). Personal announcement; see also Rosell et al (2002)Google Scholar
  182. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J, Olayabal A et al (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330(3): 153–158CrossRefPubMedGoogle Scholar
  183. Rosell R, Martin C, Balana C (1999) Ifosfamide in non-small-cell lung cancer. Ann Oncol 10(Suppl 5):S25–28CrossRefPubMedGoogle Scholar
  184. Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzoni A, Chemassani A, Bogaerts J, Gallant G (2002) Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non small cell lung cancer: a comparative multinational trial. Ann Oncol 13(10):1539–1549CrossRefPubMedGoogle Scholar
  185. Ross PJ, Rao S, Cunningham D (1998) Chemotherapy of oesophago-gastric cancer. Pathol Oncol Res 4(2):87–95PubMedGoogle Scholar
  186. Ross PJ, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20(8): 1996–2004CrossRefPubMedGoogle Scholar
  187. Rougier P, Mitry E (2000) Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 62(Suppl 1):73–78CrossRefGoogle Scholar
  188. Rougier P, Mitry E (2001) Review of the role of CPT-11 in the treatment of colorectal cancer. Clin Colorectal Cancer 1(2):87–94PubMedGoogle Scholar
  189. Rubben H, Otto T (2001) Locally advanced or metastatic bladder carcinoma. Current aspects of therapy. Urologe A 40(6):464–467CrossRefPubMedGoogle Scholar
  190. Ruszniewski P, Ducreux M, Chayvialle JA, Blumberg J, Coarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R (1996) Treatment of the carcinoid syndrome with long acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39:279–283PubMedGoogle Scholar
  191. Sabel MS, Sondak VK (2003) Is there a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma? Drugs 63(11):1053–1058PubMedGoogle Scholar
  192. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343(13):905–914CrossRefPubMedGoogle Scholar
  193. Schachter J, Brenner B, Fenig E, Gutman R, Sulkes A, Gutman H (2003) Patterns of failure in patients with malignant melanoma treated with high-dose interferon-alpha 2b in the adjuvant setting. Melanoma Res 13(1):93–96CrossRefPubMedGoogle Scholar
  194. Schiller JH, Harrington D, Sandier A, Belani C, Langer C, Krook J, Johnson DH (2000) Randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). ASCO 2000: abs 2Google Scholar
  195. Schiller JH (2001) Current standards of care in small-cell and non-small-cell lung cancer. Oncol 61(Suppl 1):3–13CrossRefGoogle Scholar
  196. Schull B, Kornek GV, Schmid K, Raderer M, Hejna M, Lenauer A, Depisch D, Lang F, Scheithauer W (2003) Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesopha-geal cancer. Oncology 65(3):211–217PubMedGoogle Scholar
  197. Sculier JP, Lafitte JJ, Berghmans T, Thiriaux J, Lecomte J, Efremidis A, Ninane V, Paesmans M, Mommen P, Klastersky J (2000) A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party. Lung Cancer 29:67–73CrossRefPubMedGoogle Scholar
  198. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ (1994) Histological typing of female genital tract tumours, 2nd edn (WHO International histological classification of tumours). Springer, Berlin Heidelberg New YorkGoogle Scholar
  199. Segal R, Winquist E, Lukka H, Chin JL, Brundage M, Markman BR (2002) Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group: Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma — a practice guideline. Can J Urol 9(5):1625–1633PubMedGoogle Scholar
  200. Sherif A, Rintala E, Mestad O, Nilsson J, Holmberg L, Nilsson S, Malmstrom PU on behalf of the Nordic Urothelial Cancer Group (2002) Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer — Nordic Cystectomy Trial 2. Scand J Urol Nephrol 36(6):419–425CrossRefPubMedGoogle Scholar
  201. Shields AF, Zalupski MM, Marshall JL, Meropol NJ (2004) Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer 100(3): 531–537CrossRefPubMedGoogle Scholar
  202. Shiga H, Rasmussen AA, Johnston PG, Langmacher M, Baylor A, Lee M, Cullen KJ (2002) Prognostic value of c-erb B2 and other markers in patients treated with chemotheray for recurrent head and neck cancer. Head Neck 22(6):599–608CrossRefGoogle Scholar
  203. Shimizu Y, Kato M, Yamamoto J, Nakagawa S, Tsukagoshi H, Fujita M, Hosokawa M, Asaka M (2004) EMR combined with chemoradiotherapy: a novel treatment for superficial esophageal squamous-cell carcinoma. Gastrointest Endosc 59(2):199–204CrossRefPubMedGoogle Scholar
  204. Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ (2003) A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II—IV breast cancer. Oncol Rep 10:715–724PubMedGoogle Scholar
  205. Skogseid B (2001) Nonsurgical treatment of advanced malignant neuroendocrine pancreatic tumors and midgut carcinoids. World J Surg 25(6):700–703CrossRefPubMedGoogle Scholar
  206. Slamon et al (abstract) (1999) Cited in Cobleigh (2000) Results from the pivotal anti-HER2 therapy chemotherapeutic combination study. ECCO, abs 1261Google Scholar
  207. Smith JA (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. Roach M 3rd, De Silvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS, Radiation Therapy Oncology Group 9413, University of California San Francisco, San Francisco, CA. J Clin Oncol 21:1904–1911. Urol Oncol 21(6):482Google Scholar
  208. Smith SR, Som P, Fahmy A, Lawson W, Sacks S, Brandwein M (2000) A Clinicopathological study of sinonasal neuroendocrine carcinoma and sinonasal undifferentiated carcinoma. Laryngoscope 110(10 Pt 1):1617–1622CrossRefPubMedGoogle Scholar
  209. Sonpavde G (2003) Bevacizumab in renal-cell cancer. N Engl J Med 349(17):1674CrossRefGoogle Scholar
  210. Sousa-Escandon A, Vazquez S, Quintero-Aldana G, Picallo JA, Neira J, Garcia-Novio F, Mateo A, Rico M, Mel JR (2002) Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: a phase II trial. Int J Urol 9(3):162–166CrossRefPubMedGoogle Scholar
  211. Spencer S, Wheeler R, Peters G, Meredith R, Beenken S, Nabel L, Wooten A, Soong SJ, Salter M (2003) Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer. Head Neck 25(2):118–122CrossRefPubMedGoogle Scholar
  212. Sporn RJ, Greenberg BR (1990) Empiric chemotherapy in patients with carcinoma of unknown primary site. Am J Med 88(1):49–55CrossRefPubMedGoogle Scholar
  213. Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, Zimmermann TM, Vogelzan NJ (2003) Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimen for metastatic renal cancer. J Urol 170(4 Pt 1):1141–1145CrossRefPubMedGoogle Scholar
  214. Sternberg CN (2003) Metastatic renal cell cancer treatments. Drugs Today (Barcelona) 39(Suppl C):39–59Google Scholar
  215. Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A (2001) Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92(12):2993–2998CrossRefPubMedGoogle Scholar
  216. Steward WP (1997) Chemotherapy for metastatic soft tissue sarcomas. Cancer Treat Res 91:157–172PubMedGoogle Scholar
  217. Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E et al (1993 a) The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult softtissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 31(Suppl 2):S241–244PubMedGoogle Scholar
  218. Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E et al (1993) Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 11(1):15–21PubMedGoogle Scholar
  219. Terando A, Sabel MS, Sondak VK (2003) Melanoma: adjuvant therapy and other treatment options. Curr Treat Options Oncol 4(3):187–199PubMedGoogle Scholar
  220. The ATAC (Armidex, Tamoxifen Alone or in Combination) Trialists’ Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. The Lancet Vol 359, June 22, www.thelancet.comGoogle Scholar
  221. Thomas M, Rube C, Semik M, von Eiff M, Freitag L, Macha HN, Wagner W, Klink F, Scheld HH, Willich N, Berdel WE, Junker K (1999) Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 17(4):1185PubMedGoogle Scholar
  222. Tonato M (2002) Consensus conference on medical treatment of non-small cell lung cancer: adjuvant treatment. Lung Cancer 38(Suppl 3):S37–42CrossRefGoogle Scholar
  223. Tourani JM, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero JM, Mayeur D, Rixe O, Sun XS, Bernard O, Andre T, Tournigand C, Muracciole X, Guilhot J (2003) Subcutaneous Administration Propeukin Program Cooperative Group: Subcutaneous interleukin-2 and interferon alpha administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study swith sequential analysis design. J Clin Oncol 21:3987–3994CrossRefPubMedGoogle Scholar
  224. Treat J (2003) Weekly topotecan in the management of lung cancer. Lung Cancer 41(Suppl 4):S27–31CrossRefPubMedGoogle Scholar
  225. Trump DL (2002, 2003) Biculatamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen OM, Persson BE, Carroll K, Kolvenbag GJ, Casodex Ear Prostate Cancer Trialist Group, Medical College of Wisconsin, Milwaukee, WI. J Urol 168:429–435, 2002. Urol Oncol 21(5):408–409Google Scholar
  226. Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340(4): 265–271CrossRefPubMedGoogle Scholar
  227. Urba SG, Chansky K, Van Veldhuizen PJ, Pluenneke RE, Benedetti JK, Macdonald JS, Abbruzzese JL for the Southwest Oncology Group (2004) Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study. Invest New Drugs 22(1):91–97CrossRefPubMedGoogle Scholar
  228. Urba SG, Orringer MB, Ianettonni M, Hayman JA, Satoru H (2003) Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 98(10):2177–2183CrossRefPubMedGoogle Scholar
  229. Valentino J, Spring PM, Shane M, Arnold SM, Regine WF (2002) Interval pathologic assessment in patients treated with concurrent hyperfractionated radiation and intraarterial cisplatin (HYPERRADPLAT). Head Neck 24(6): 539–544CrossRefPubMedGoogle Scholar
  230. Verheul HM, Pinedo HM (2003) Vascular endothelial growth factor and its inhibitors. Drugs Today (Barcelona) 39(Suppl C):81–93Google Scholar
  231. Vogel CL, Franco SX (2003) Clinical experience with trastuzumab (herceptin). Breast J 9(6):452–462CrossRefPubMedGoogle Scholar
  232. Vogel C, Cobleigh M, Tripathy D, Harris L, Fehrenbacher L, Slamon D, Ash M, Novotny W, Stewart S, Shak S (2000) First-line non-hormonal treatment of women with Her2-overexpressing metastatic breast cancer with herceptin (Trastuzumab, humanized anti-HER2-antibody). ASCO meeting 2000, Aventure, Fla, abstract 275Google Scholar
  233. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3):719–726CrossRefPubMedGoogle Scholar
  234. Vose J, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21(3): 514–519CrossRefPubMedGoogle Scholar
  235. Wachter S, Wachter-Gerstner N, Potter R (2003) Neoadjuvant hormonal treatment and radiotherapy for prostate cancer. Oncology 65(Suppl 1):29–33CrossRefGoogle Scholar
  236. Wagner G (ed) (1993) Tumorlocalisationsschliissel, 5th edn. Springer, Berlin Heidelberg New YorkGoogle Scholar
  237. Waldherr C, Schumacher T, Pless M, Crazzolara A, Maecke HR, Nitzsche EU, Haldemann A, Müller-Brand J (2001) Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. Nucl Med Commun 22(6):673–678CrossRefPubMedGoogle Scholar
  238. Waldherr C, Schumacher T, Meacke HR, Nitzsche EU, Müller-Brand J (2001) Radionuclide therapy of somatostatin-receptor-positive tumors using (90-Y-DOTA)-D-Phe1-Tyr3-octreotide (90Y-DOTATOC): the Basle experience. Schweiz Krebs Bull 21:65–68Google Scholar
  239. Weiss E, Richter S, Hess CF (2003) Radiation therapy of the pelvic and paraaortic lymph-nodes in cervical carcinoma: a prospective three-dimensional analysis of patient positioning and treatment technique. Radiother Oncol 68(1):41–49CrossRefPubMedGoogle Scholar
  240. Weissbach L, Miller K (eds) (1998) Diagnostische und therapeutische Standards in der Urologischen Onkologie. Zuckschwerdt, Munich Berne Vienna New YorkGoogle Scholar
  241. Weissbach L, Miller K (1998) Leitlinien zur Diagnostik und Therapie des Harnblasenkarzinoms. Urologe (A) 37:440–457CrossRefGoogle Scholar
  242. Wheatley K, Ives N, Hancock B, Gore M (2002) Interferon as adjuvant treatment for melanoma. Lancet 360(9336): 878CrossRefGoogle Scholar
  243. Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ, Weber WA (2004) Time course of tumor metabolic activity during chemotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22(5):900–908CrossRefPubMedGoogle Scholar
  244. Wilke H, Achterrath W, Schmoll HJ, Gunzer U, Preusser P, Lenaz L (1988) Etoposide and split-dose cisplatin in small-cell lung cancer. Am J Clin Oncol 11(5):572–578PubMedGoogle Scholar
  245. Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP (2003) American Society of Clinical Oncology: Technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 21(13): 2597–2599CrossRefPubMedGoogle Scholar
  246. Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP (2002) American Society of Clinical Oncology: Technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 20(15):3317–3327CrossRefPubMedGoogle Scholar
  247. Winquist E, Kirchner TS, Segal R, Chin J, Lukka H for Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative (2004) Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 171(2 Pt 1):561–569CrossRefPubMedGoogle Scholar
  248. Wittekind C, Wagner G (1997) TNM-Klassifikation maligner Tumoren, 5th edn. Springer, Berlin Heidelberg New YorkGoogle Scholar
  249. Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA (2002) A Phase I trial of 90 Y-anti-carcinoembryonic antigen chi-meric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 9(16 Pt 1):5842–5852Google Scholar
  250. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–434CrossRefPubMedGoogle Scholar
  251. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Roger-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21(16):3127–3132CrossRefPubMedGoogle Scholar
  252. Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B, Hubers D, Spalding S, Braun T, Ferrara JL, Hutchinson RJ (2002) Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 15, 20(8):2142–2149CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • K. Possinger
  • A. Schauer
  • F. Griesinger
  • A. C. Roever

There are no affiliations available

Personalised recommendations